8-K 1 d8k.txt FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 12, 2002 -------------------------------------- Date of Report (Date of earliest event reported) IMMUNEX CORPORATION -------------------------------------------------------------------------------- (Exact Name of Registrant as Specified in Charter) Washington 0-12406 51-0346580 -------------------------------- ----------------------- -------------------- (State or Other Jurisdiction (Commission File No.) (IRS Employer of Incorporation) Identification No.) 51 University Street, Seattle, Washington 98101 -------------------------------------------------------------------------------- (Address of Principal Executive Offices) (Zip Code) (206) 587-0430 -------------------------------------------------------------------------------- (Registrant's Telephone Number, Including Area Code) None -------------------------------------------------------------------------------- (Former Name or Former Address, if Changed Since Last Report) Item 5. Other Events. On April 12, 2002, Immunex Corporation, a Washington corporation ("Immunex"), entered into an ENBREL Supply Agreement with Genentech, Inc., a Delaware corporation ("Genentech"). Under the Supply Agreement, Genentech will manufacture commercial quantities of ENBREL (R) (etanercept) at its manufacturing facility in South San Francisco, California. Subject to approval by the Food and Drug Administration, the facility is expected to supply capacity for ENBREL beginning in 2004. Item 7. Financial Statements, Pro Forma Financial Information and Exhibits. (c) Exhibits. 10.1* ENBREL Supply Agreement, dated April 12, 2002, by and between Immunex Corporation and Genentech, Inc. 99.1 Immunex press release dated April 15, 2002. -------------------- * Confidential treatment requested. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNEX CORPORATION Dated: May 6, 2002 By /s/ Barry G. Pea ------------------------------------ Name: Barry G. Pea Its: Executive Vice President, General Counsel and Secretary EXHIBIT INDEX Exhibit Number Description -------------- ----------- 10.1* ENBREL Supply Agreement, dated April 12, 2002, by and between Immunex Corporation and Genentech, Inc. 99.1 Immunex press release dated April 15, 2002. -------------------- * Confidential treatment requested.